New Drug Targets Oral Cancer’s Deadliest Forms
A cutting-edge oral cancer therapy is moving closer to reality thanks to a $400,000 National Institutes of Health grant awarded to UT Health San Antonio and biotech startup Keraceuticals. Their first-in-class drug, CIDD99, could finally…